carmustine / Generic mfg. - LARVOL DELTA

Leptomeningeal and Ependymal Seeding of a High-Grade Glioma Following Ventricular Opening and Carmustine Wafer Implantation: A Case Report Highlighting a Diagnostic Dilemma. (PubMed, Cureus) - "At the same time, a patient awaits formal oncologic evaluation, a wait that is often prolonged in publicly funded health systems. We review the reported evidence on risk factors for cerebrospinal fluid (CSF) dissemination, carmustine-related complications near the ventricular system, the role of MRS when lumbar puncture is contraindicated, and the relevance of the 2021 WHO nomenclature for interpreting this case."

Journal • Anaplastic Astrocytoma • Astrocytoma • Brain Cancer • CNS Disorders • Glioblastoma • Glioma • High Grade Glioma • Infectious Disease • Oncology • Solid Tumor • IDH1

CALGB 51101: Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma (clinicaltrials.gov) - P2 | N=113 | Completed | Sponsor: Alliance for Clinical Trials in Oncology | Active, not recruiting ➔ Completed

Trial completion • B Cell Lymphoma • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Transplantation

Intranasal Delivery of Solid Lipid Nanoparticles Loaded with Carmustine and Temozolomide for Glioblastoma Treatment in Mice. (PubMed, AAPS PharmSciTech) - "However, further rigorous evaluations regarding local nasal mucosal toxicity and long-term renal accumulation are required to fully establish the safety limits of this carrier system. Overall, intranasally administered SLNs provide a promising nanoparticle-based strategy that offers a viable, low-toxicity alternative to improve clinical outcomes in aggressive brain tumors."

Journal • Preclinical • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Successful Autologous Hematopoietic Stem Cell Transplantation in HIV-Associated Primary CNS Lymphoma (SOHO 2026) - "He underwent thiotepa/carmustine-conditioned auto-HSCT with neutrophil engraftment at day +18 and platelet recovery at day +19. This case demonstrates that auto-HSCT is feasible and effective in HIV-associated PCNSL despite profound baseline immunosuppression. It challenges historical contraindications to transplantation in PLWH with CNS disease and supports reconsideration of eligibility criteria for curative-intent therapies and clinical trials. ART: antiretroviral therapy; auto-HSCT: autologous hematopoietic stem cell transplantation; CD: cluster of differentiation; CNS: central nervous system; DLBCL: diffuse large B-cell lymphoma; HIV: human immunodeficiency virus; MATRix: methotrexate, cytarabine, thiotepa, and rituximab; PCNSL: primary CNS lymphoma; PLWH: people living with HIV; R-MPV: rituximab plus high-dose methotrexate, procarbazine, and vincristine."

B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • CD34

Concurrent Chronic Active Epstein-Barr Virus Disease and Extranodal NK/T-Cell Lymphoma as an Isolated Orbital Recurrence After Autologous Stem Cell Transplantation: A Case Report (SOHO 2026) - "She received reduced-dose dexamethasone, cisplatin, gemcitabine, pegaspargase (DDGP) with partial metabolic response after 3 cycles. Our case demonstrates that CAEBV-associated clonal T-cell disease and ENKTL can coexist in the same anatomic site, highlighting the importance of integrated clinical, morphologic, immunophenotypic, and molecular evaluation. ASCT: autologous stem cell transplantation; BEAM: carmustine, etoposide, cytarabine, and melphalan; CD: cluster of differentiation; CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone; DDX3X: DEAD-box helicase 3 Xlinked; EBER: EBV-encoded small RNA; EBV: Epstein-Barr virus; KMT2D: lysine methyltransferase 2D; MRI: magnetic resonance imaging; NK: natural killer; PCR: polymerase chain reaction; TCR: T-cell receptor; TIA-1: T-cell intracellular antigen-1."

Case report • Clinical • IO biomarker • Extranodal Natural Killer/T-cell Lymphoma • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • CD2 • CD4 • CD5 • CD7 • CD8 • DDX3X • KMT2D • NCAM1

Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial. (PubMed, J Clin Oncol) - P=N/A | "Shorter time to relapse was the strongest predictor of subsequent relapse. Allogeneic SCT offers a chance for cure in patients with high-risk ALCL relapse. For early relapsed ALCL autologous SCT was not effective. Vinblastine monotherapy achieved cure in patients with late relapse; however, it was not effective for early relapses."

Clinical • Journal • Monotherapy • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • Transplantation

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. (PubMed, Leukemia) - "Enrolled patients were randomly assigned to receive methotrexate-cytarabine (arm A), or methotrexate-cytarabine-rituximab (B), or methotrexate-cytarabine-thiotepa-rituximab (MATRix; arm C). A second randomization allocated patients with responsive/stable disease to whole-brain irradiation (WBRT) or carmustine-thiotepa-conditioned autologous transplantation (ASCT)...Importantly, MATRix and ASCT did not result in higher non-relapse mortality or second tumors incidence. Patients who received WBRT experienced impairment in attentiveness and executive functions, whereas patients undergoing ASCT experienced improvement in these functions as well as in memory and quality of life."

Journal • Alzheimer's Disease • CNS Disorders • CNS Lymphoma • Cognitive Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial. (PubMed, Lancet) - P3 | "In the largest randomised trial in untreated PCNSL to date, HCT-ASCT significantly improved progression-free and overall survival compared with non-myeloablative consolidation in patients who had completed induction treatment, establishing it as the preferred consolidation strategy in fit patients."

Journal • P3 data • Acute Myelogenous Leukemia • Cardiovascular • CNS Lymphoma • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Pulmonary Embolism • Respiratory Diseases • Transplantation

From Paralysis to First Steps: A Case of Neurolymphomatosis Associated With Diffuse Large B-Cell Lymphoma (SOHO 2026) - "Reinduction chemotherapy, followed by ASCT (carmustine/thiotepa conditioning), was complicated by multiorgan failure and septic shock requiring multi-vasopressor ICU support. This underscores that aggressive treatment can yield favorable outcomes, even in morbid clinical scenarios. CD: cluster of differentiation, CSF: cerebrospinal fluid, ICU: intensive care unit, MRI: magnetic resonance imaging, PET/CT: positron emission tomography/computed tomography, RMTX/Ara-C: rituximab, methotrexate, cytarabine."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • MME • PTPRC

SEVEN-YEAR FOLLOW-UP OF THE IELSG42 "MARIETTA" PHASE II TRIAL: DURABLE REMISSIONS FOLLOWING MATRix/RICE INDUCTION AND THIOTEPA AUTOGRAFT IN SECONDARY CNS LYMPHOMA (ICML 2025) - "Introduction: The primary analysis of the MARIETTA study, the largest prospective trial focusing on secondary CNS lymphoma (SCNSL), demonstrated the activity of multi-agent chemotherapy with MATRix (rituximab, methotrexate, cytarabine, and thiotepa) and RICE (rituximab, etoposide, ifosfamide, carboplatin) followed by carmustine/thiotepa (BCNU/TT)-ASCT. Long-term follow-up of the international MARIETTA study demonstrates durable remissions in pts with SCNSL able to proceed to BCNU/TT-ASCT. A more favourable outcome was seen in pts with de novo SCNSL or iso-CNS-R. Conversely, outcomes remain poor in pts who did not proceed to ASCT and those with synch-CNS-R."

Clinical • P2 data • Chronic Lymphocytic Leukemia • CNS Lymphoma • Hematological Malignancies • Lymphoma • Oncology • Secondary Central Nervous System Lymphoma

A Window Study of Acalabrutinib & Rituximab, Followed By Chemotherapy & Autograft (ASCT) in Fit Patients with Treatment Naïve Mantle Cell Lymphoma (MCL): First Report of the Investigator-Initiated Australasian Leukaemia & Lymphoma Group NHL33 'Wamm' Trial (ASH 2023) - P2 | "RDHAOx chemotherapy (rituximab, dexamethasone, cytarabine, oxaliplatin) prior to ASCT provides a complete response (CR) rate of 77% and favourable toxicity compared to many induction regimens (Le Gouill Blood 2017). Furthermore, Obinutuzumab-DHAP yields undetectable minimum residual disease (MRD) in 85% of young MCL patients...Those with an objective response (CR or partial response-PR) underwent BEAM ASCT (carmustine, etoposide, cytarabine, melphalan) then AR maintenance (A; 1yr continuous & R; 3-monthly x 8 cycles)...An AR window yields a high ORR and compared to historical studies, improves post-chemo induction CR rates and MRD negativity. A telehealth model allowed rapid recruitment in a rare cancer."

Clinical • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Neutropenia • Oncology • Pneumonia • Thrombocytopenia • TP53

Myeloablative Vs. Non-Myeloablative Consolidation for Primary Central Nervous System Lymphoma: Results of Alliance 51101. (PubMed, Blood Adv) - P2 | "Patients, age 18-75 years, were randomly assigned in a 1:1 manner to induction therapy (methotrexate, temozolomide, rituximab and cytarabine) followed by consolidation with either thiotepa plus carmustine and autologous stem cell rescue versus induction followed by non-myeloablative, infusional etoposide plus cytarabine (EA) The primary endpoint was progression-free survival (PFS). Both consolidative strategies yielded encouraging efficacy and similar toxicity profiles. Clinicaltrials.gov (NCT01511562)."

Journal • Bone Marrow Transplantation • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

LACE-Conditioned Autologous Stem Cell Transplantation in Lymphoma: A Safe and Effective Regimen (SOHO 2026) - "Lomustine, cytarabine, cyclophosphamide, and etoposide (LACE) conditioning has been reported as an effective alternative to BEAM with a favorable mucositis profile. LACE-conditioned HDT-ASCT demonstrates favorable long-term survival outcomes across lymphoma subtypes, with low day 100 mortality (2.9%) and a favorable toxicity profile. Older age and extranodal disease were independent adverse prognostic factors. These findings support LACE as a safe and effective conditioning strategy in both relapsed/refractory and consolidative ASCT settings."

B Cell Lymphoma • Classical Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study. (PubMed, Bone Marrow Transplant) - P3 | "BEAM (Carmustine, Etoposide, Aracytine, Melphalan) is among the most frequently used conditioning regimen...Each patient from the BeEAM cohort (n = 30) was matched to three patients from the R-BEAM cohort (n = 90) for age, sex, MIPI score, pre-transplant status disease and rituximab maintenance (RM). PFS and OS at 2 years remained similar between R-BEAM and BeEAM with more renal toxicity in BeEAM group. MCL patients who received R-DHAP induction before ASCT have similar outcome after R-BEAM or BeEAM conditioning regimen."

Journal • Retrospective data • Bone Marrow Transplantation • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology • Transplantation

Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study. (PubMed, Lancet Haematol) - P1 | "Anti-CD30 CAR T-cell infusion as consolidation after BEAM and autologous HSCT is safe, with low rates of toxicity and encouraging preliminary activity in patients with Hodgkin lymphoma at high risk of relapse, highlighting the need for larger studies to confirm these findings."

CAR T-Cell Therapy • Journal • P1 data • Bone Marrow Transplantation • Genito-urinary Cancer • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Leukopenia • Lung Cancer • Lymphoma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • T Cell Non-Hodgkin Lymphoma • Testicular Cancer • Transplantation

Yttrium-90 Anti-CD25-BEAM-Conditioning for Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphoma. (PubMed, Blood Adv) - P1 | "In this phase 1 clinical trial, we tested the addition of beta-emitting 90Y-labeled chimeric anti-CD25 basiliximab (aTac) to BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning for AHCT in patients with PTCL. 90Y-aTac-BEAM appears to be safe as an AHCT conditioning regimen for PTCL, with no increased toxicity over the toxicities historically seen with BEAM alone in this patient population. This trial was registered at www.clinicaltrials.gov as # NCT02342782."

Journal • Hematological Malignancies • Lymphoma • Mucositis • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Transplantation

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (clinicaltrials.gov) - P2 | N=16 | Recruiting | Sponsor: Leland Metheny | Trial completion date: Dec 2026 ➔ Mar 2027 | Trial primary completion date: Jun 2026 ➔ Nov 2026

Trial completion date • Trial primary completion date • Brain Cancer • Glioblastoma • Gliosarcoma • Oncology • Sarcoma • Solid Tumor • IDH1 • IDH2

Multi-Omics Integration Identifies a Five-Gene Metabolic Signature With Experimental Validation in Clear Cell Renal Cell Carcinoma. (PubMed, Cancer Rep (Hoboken)) - "This study establishes a precision oncology framework for ccRCC by functionally linking metabolic biomarkers, immunophenotypes, and stratified therapeutic strategies. Importantly, we identify SUCLA2 as a potential functional tumor suppressor and a promising target for further mechanistic and translational investigation."

Biomarker • Journal • Tumor mutational burden • Clear Cell Renal Cell Carcinoma • Dyslipidemia • Genito-urinary Cancer • Metabolic Disorders • Oncology • Solid Tumor • ACAT1 • HMGCS2 • TMB

FIL FLAZ12: A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL) (clinicaltrials.gov) - P3 | N=159 | Completed | Sponsor: Fondazione Italiana Linfomi - ETS | Active, not recruiting ➔ Completed

Trial completion • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

CNS-PHLAT: CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Washington University School of Medicine | Trial completion date: Jul 2029 ➔ Jul 2030 | Trial primary completion date: Jul 2027 ➔ Jul 2028

Trial completion date • Trial primary completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Secondary Central Nervous System Lymphoma • Transplantation • BCL2 • BCL6 • MYC

Comprehensive study of the tumor immune microenvironment and the prognostic significance of reticulocalbin-1: a pan-cancer analysis. (PubMed, Funct Integr Genomics) - "Drug-specific responses to RCN1 expression were probed for cisplatin, irinotecan, carmustine and lomustine, which are the common chemotherapeutic agents used in glioma clinical treatment. In particular, RCN1 is closely associated with the immune microenvironment and endoplasmic reticulum stress during tumorigenesis. In addition, RCN1 has broad prospects in guiding tumor chemotherapy pending physiological in vivo validation."

Biomarker • Journal • Brain Cancer • Glioma • Oncology • Solid Tumor

Pirtobrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL (clinicaltrials.gov) - P2 | N=28 | Not yet recruiting | Sponsor: Ruijin Hospital

New P2 trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Lymphoma • Oncology

Efficacy of BEAM versus BeEAM conditioning regimens in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: a retrospective single-center study. (PubMed, Front Oncol) - "The BEAM regimen (carmustine, etoposide, cytarabine, melphalan) is the standard conditioning regimen for autologous hematopoietic stem cell transplantation (auto-HSCT) in diffuse large B-cell lymphoma (DLBCL). Due to global carmustine shortages, bendamustine-based BeEAM has been proposed as an alternative...In summary, BEAM may be associated with better outcomes than BeEAM in this cohort. However, due to the limited sample size, these findings should be interpreted as exploratory, and larger prospective studies are needed to validate these observations."

Journal • Retrospective data • B Cell Lymphoma • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

The Role of Cellular Glutathione Redox Cycle and Glutathione in the Regulation of Ileum Contractility. (PubMed, Int J Mol Sci) - "Increasing concentrations of BCNU as well as a single EC50 BCNU dose significantly reduced both contraction amplitude and GR activity...The correlation analysis showed a negative relationship between contractility and non-protein thiols, and positive correlations between catalase and GPx activities in BCNU treated ileum, as well as between GPx and non-protein thiols in solvent controls. The results present a framework for how glutathione turnover and ileum contractility are linked."

Journal • CAT

Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=25 | Completed | Sponsor: Case Comprehensive Cancer Center | Active, not recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ Nov 2025

Trial completion • Trial completion date • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation